Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-06-07, Stock:LLY, The news for the past five days is as follows:
2018-05-31: NEWS1: Lilly to Participate in Goldman Sachs Global Healthcare Conference.NEWS2: How GlaxoSmithKline’s Segments Performed in Q1 2018.NEWS3: Top Diabetes Stocks to Buy Today.NEWS4: Top Diabetes Stocks to Buy Today.NEWS5: How Novartis’s Valuation Compares.NEWS6: Top Diabetes Stocks to Buy Today.NEWS7: The Zacks Analyst Blog Highlights: Chevron, Wells Fargo, Eli Lilly, FedEx and Valero.NEWS8: The Zacks Analyst Blog Highlights: Chevron, Wells Fargo, Eli Lilly, FedEx and Valero.NEWS9: 3 Biotechs With Huge FDA Decisions in June.NEWS10: 3 Biotechs With Huge FDA Decisions in June.NEWS11: The Zacks Analyst Blog Highlights: Chevron, Wells Fargo, Eli Lilly, FedEx and Valero.NEWS12: 3 Biotechs With Huge FDA Decisions in June.
2018-06-01: NEWS1: Lilly gets U.S. nod for arthritis drug, sets price well below rivals.NEWS2: FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis.NEWS3: FDA approves lower dose of Lilly-Incyte arthritis drug.NEWS4: A Closer Look at Novartis’s Innovative Medicine Business.NEWS5: Lilly to Showcase New Data at Digestive Disease Week 2018 for Mirikizumab in Moderate-to-Severe Ulcerative Colitis.NEWS6: Can Nektar Therapeutics Disrupt This $20 Billion Market?.NEWS7: Can Nektar Therapeutics Disrupt This $20 Billion Market?.
2018-06-04: NEWS1: Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis.NEWS2: Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis.NEWS3: Merck's (MRK) Keytruda Lung Cancer Data in Focus at ASCO.NEWS4: Merck's (MRK) Keytruda Lung Cancer Data in Focus at ASCO.NEWS5: Eli Lilly&apos;s Olumiant Gets FDA Nod for Rheumatoid Arthritis.NEWS6: FDA Nod For LLY/INCY RA Drug, JAZZ Hits Right Tones, SLS' Study Stopped Early.NEWS7: FDA Nod For LLY/INCY RA Drug, JAZZ Hits Right Tones, SLS' Study Stopped Early.
2018-06-05: NEWS1: Health Care Sector Update for 06/05/2018: MYL,VKTX,PLX,LLY.NEWS2: Health Care Sector Update for 06/05/2018: MYL,VKTX,PLX,LLY.NEWS3: Lilly Recommends Shareholders Reject Below-Market Mini-Tender Offer by TRC Capital Corp..NEWS4: Health Care Sector Update for 06/05/2018: VKTX,PLX,LLY.NEWS5: Health Care Sector Update for 06/05/2018: VKTX,PLX,LLY.NEWS6: Merck Presents Positive Melanoma Data on Keytruda at ASCO.NEWS7: Merck Presents Positive Melanoma Data on Keytruda at ASCO.NEWS8: DDW 2018: Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial.NEWS9: Health Care Sector Update for 06/05/2018: PLX, VKTX, LLY.NEWS10: Health Care Sector Update for 06/05/2018: PLX, VKTX, LLY.NEWS11: FDA Expands Lilly's ALIMTA® (pemetrexed) Label to Include Combination with KEYTRUDA® (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression.NEWS12: Eli Lilly: FDA Expands ALIMTA Label To Include Combination With KEYTRUD.NEWS13: Eli Lilly: FDA Expands ALIMTA Label To Include Combination With KEYTRUD.
2018-06-06: NEWS1: How Did Eli Lilly Perform in May?.NEWS2: Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive.NEWS3: Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive.NEWS4: Major M&A Deals in Pharmaceutical Sector in May and June.

Answer: Decrease